SEC Filings
ImmunityBio Targets Earlier Bladder Cancer Treatment After ANKTIVA Combination Outperforms BCG Alone
The company targets an FDA application by year-end 2026 to reach patients receiving BCG for the first time.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
The company targets an FDA application by year-end 2026 to reach patients receiving BCG for the first time.
Deals
Leggett & Platt lifted total sales, but acquisition costs weighed on reported profit as adjusted earnings rose.
Deals
Adjusted quarterly earnings rose 88%, while CNH agreed to sell majority control of its construction business to Kobelco.
SEC Filings
Expected sale proceeds support $3 billion in buybacks across 2026 and 2027, plus $3 billion of planned debt reduction in 2027.
Deals
The Swiss drug developer proposes 10,294,117 IPO shares as it funds antibody trials for respiratory and skin diseases.
SEC Filings
The loan agreement offers another $835.0 million in delayed funding and requires no collateral or subsidiary guarantees.
Earnings
The terminated contract leaves no future obligations, but Berkshire’s remaining legacy policies still carry $7.2 billion of future earnings charges.
Deals
Adjusted earnings rose 85% in preliminary estimates, while net interest expense reached $163 million.
SEC Filings
The new bonds mature in 2034 and carry a 7.125% rate, compared with 5.50% on the $500 million of notes slated for redemption.
SEC Filings
The purchase uses Friday’s closing price, while future repurchases must leave Argon’s recorded stake at or below 14.9%.
SEC Filings
Small uncontrolled studies also showed lupus kidney responses and systemic sclerosis improvement, with a myositis approval filing planned for 2028.
Earnings
Operating earnings fell to $12,705 million in the third quarter, while Berkshire spent approximately $9.6 billion buying back shares.